Important results from the project
The original goals were:
Objective 1. Upgrade the business plan with high quality plans for the preclinical and clinical studies, where required.
Objective 2. Map the strengths, weaknesses and opportunities that exist in terms of IP for Mim; develop a strategic plan based on this.
Objective 3. Purposefully maintain existing and create new investor relationships.
All these objectives were met.
Expected long term effects
Our discovery has come from strong academic work led by Pete Williams at Karolinska Institutet.
Through Vinnova, we have been able to process this project from academic science to a more commercial whole. This is important to advance our drug development and provide strong planning to attract larger funding (eg pharmaceutical companies, VC) to take this invention to the clinic.
The long-term benefit will be a new medicine for neurodegenerative disease.
Approach and implementation
Progress 1. Preclinical consultation with Truly Translational completed.
Progress 2. Development of business plan in collaboration with KI Innovations and consultation with Ingela Hallberg. New market analysis carried out with FHC Undelund. The PCT for the patent was filed in February. A plan is in place for the international proposal 2025.
Progress 3. New meetings with Sciety, Life Science Invest, BeiGene, AbbVie. Additional meetings with committed (not active) investors inc. Genentech.
External links
The project description has been provided by the project members themselves and the text has not been looked at by our editors.
